Tissue factor (TF) is a transmembrane glycoprotein that is a major physiological initiator of blood coagulation. Its expression was detected in epithelial tissues of the skin, mucosal surfaces of the gut and genitourinary system ([@bib6]). Abnormal expression of TF was reported in different types of cancers, including gastric ([@bib26]), non-small cell lung ([@bib10]; [@bib18]), breast ([@bib24]), pancreatic ductal ([@bib15]), colorectal ([@bib8]; [@bib20]; [@bib19]; [@bib14]), hepatocellular ([@bib16]) and prostate carcinoma ([@bib1]).

A review in 2003 ([@bib17]) summarised its role in inducing angiogenesis-related metastasis to be both clotting-dependent and -independent. TF when bound to its natural ligand, FVIIa to form the TF:FVII complex activates anti-apoptotic kinases, which could drive cancer metastasis ([@bib21]). In baby hamster kidney cells, TF overexpression potently reversed hallmarks of apoptosis ([@bib21]). FVIIa and TF also promote the survival of cells able to undergo anoikis (a special form of apoptosis when cells detach from extracellular matrix and lack adhesion signalling) ([@bib23]). [@bib7] designed an icon (immunoconjugate molecule) that localised selectively to TF-expressing cells. When injected into xenografted human prostate cancer and melanoma, it resulted in significant tumour debulking.

TF is also implicated in regulation of the synthesis of the pro-angiogenic vascular endothelial growth factor (VEGF) by tumour cells. When tumour cells were transfected to express TF in a murine xenograft model, they grew rapidly and established larger and more vascularised tumours than controls ([@bib2]). Increased TF positivity has been correlated with increased vascular density, clinical stage and Duke\'s classification in colorectal cancers ([@bib22]).

A relationship between elevated TF expression and poor prognosis in advanced-stage intestinal gastric cancer was shown in the Japanese population ([@bib26]). In Japan, distal tumours tend to predominate in gastric cancers, in contrast to an increasing incidence of proximal gastric tumours in the West ([@bib13]). The different distribution for the site of gastric cancers in these two populations may suggest separate biological entities and variations in respective TF expressions and clinical outcomes. This is the first study to examine TF expression in gastric adenocarcinoma in a European population. Correa proposed that the intestinal-type gastric cancer sequentially transformed from normal mucosa into atrophic gastritis, intestinal metaplasia, dysplasia and finally to invasive adenocarcinoma in a very similar fashion to the multi-step sequence of events from precancerous changes to invasive disease in colorectal cancer ([@bib4]). This is subsequently supported by extensive studies by Keller *et al* ([@bib9]), although controversies still exist. We also studied the expression of TF along carcinogenic metaplasia--adenoma--carcinoma sequence (MACS) of gastric cancer.

Materials and methods
=====================

Patients and materials
----------------------

Specimens were obtained from the histopathology archive of the Department of Histopathology, South Manchester University Hospital NHS Trust and the Department of Pathology, Wigan Infirmary. The study was approved by the Tameside and Glossop Ethics Committee (03/TG/560). A retrospectively compiled database was established of 251 patients who underwent surgery for primary gastric and gastro-oesophageal tumours at the South Manchester University Hospital NHS Trust between 1995 and 2004. Certain groups of patients were excluded from the study, including those of Siewart type I (*n*=22) and those who underwent neoadjuvant therapy (*n*=31), emergency surgery (*n*=1) or died after surgery (*n*=25). Tissue microarrays (TMAs) were were available for 160 patients, 122 of whom were male, with median age of 67 (range 30--85) years. The TNM seventh edition was used for all staging purposes. The 160 gastric cancer patients comprised stage 0 (*n*=2), stage I (*n*=27), stage II (*n*=52), stage III (*n*=68) and stage IV (*n*=11) disease. The patients underwent either partial or subtotal gastrectomies (*n*=38), total gastrectomy (*n*=37), proximal gastrectomy (*n*=4) or oesophago gastrectomy (*n*=80) and completion gastrectomy (*n*=1). After surgery, patients were seen in the surgical outpatient clinic. The median period for follow-up was 7.9 years (range: 4.0--13.3 years). Thirteen normal tissue samples were available: 7 from males with mean age of 61 years. Eighteen intestinal metaplasia samples, of which 5 were from males with mean age of 68 years, were also included in this study ([Table 1](#tbl1){ref-type="table"}).

Immunohistochemical staining of TF (CD142)
------------------------------------------

Four tumour cores were available for each patient, of which two were from the centres and two from the invasive edges of the resected tumour. All specimens were stained within 2 months of cutting to minimise antigen deterioration. The polymeric method, more specifically the Super-Sensitive Detection System (Biogenex Laboratories, Fremont, CA, USA), which incorporates a 'Super Enhancer\', to boost the effects of the polymeric-HRP secondary antibody was used. Sections 4-*μ*m thick were deparaffinised in xylene and rehydrated before microwaving in the 0.05 ℳ Tris-HCl/1 mℳ EDTA buffer (pH 9.0) for 25 min at high power. The sections were then allowed to cool in the buffer for 20 min. After a 5-min wash in Tris-buffered saline (TBS), blocking steps were followed according to the manufacturer\'s guidelines using hydrogen peroxide solution and 10% casein. After the casein solution was tapped off, Mouse Monoclonal Antibody no.4509 (American Diagnostica Inc., Stamford, CT, USA) diluted at 1 : 250 in TBS was applied and incubated in the humidified chamber for 1 h at room temperature. TBS washing was repeated and Biogenex Super Enhancer Solution was applied and sections were incubated for 20 min at room temperature. After washing with TBS, the Biogenex Polymer HRP Secondary was applied and sections were incubated for 30 min at room temperature. After washing, DAB+ solution was applied at 1 : 50 dilution and the samples were left covered for 5 min. Sections were then washed with water, counterstained with haematoxylin for 1 min, alkaline dipped, dehydrated and mounted. Whole sections of 14 high and 14 low staining for TF were stained with CD31/CD34, markers of microvascular density (MVD). Antigen retrieval was carried out by microwaving for 25 min in 10 mℳ sodium citrate (pH 6.0) (Sigma-Aldrich, Poole, UK) buffer solution. After quenching endogenous peroxidase, non-specific binding was blocked using 10% casein solution (Vector Laboratories Inc., Peterborough, UK). A mixture of primary antibodies, mouse monoclonal anti-CD31 (M0823, Dako Ltd., Ely, UK) and anti-CD34 (M7165, Dako Ltd), both at dilution 1 : 70, was applied and the sections were incubated overnight at 4 °C. After washing and application of biotinylated rabbit anti-mouse secondary antibody, detection was completed using Vectastain ABC-AP Kit (SK-5100, Vector) according to the manufacturer\'s instructions using Vector Red (SK-5000, Vector) chromogen and haematoxylin counterstain.

Assessment of TF staining in the gastric cancer samples
-------------------------------------------------------

Staining for TF was isolated to the cytoplasm and basement membrane of expressing cells. Only tumour cells were scored as positive. Lymphocytes, mast cells, parietal and chief cells at the basal pits of the normal gastric mucosa were also prone to strong staining but were not scored. Both the intensity and percentage of staining were scored. The intensity was scored on a scale from 0 to 4 with 0 for negative uptake, 1 for weak, 2 for moderate, 3 for strong and 4 for very strong staining. Heterogeneous staining and slight background staining was noted in most of the TMA core samples studied. In a sample where there was weak, moderate and strong staining in different proportions, the strongest staining and its percentage was recorded. The immunoreactivity of TF was evaluated as positive when the intensity score was ⩾3 and \>10% of the carcinoma cells were stained in the case of assessing for the strongest intensity. The intensity for the majority of tumour cells stained and its percentage were also recorded for further analysis. Assessment of immunoreactivity was performed by an individual (LL) without background knowledge of the specimens and then assessed by another team member (SH). Inter-observer variability was \<23%.

Statistical analysis
--------------------

Data were analysed using S-Plus 2000 and appropriate non-parametric tests were used to investigate TF expression and clinicopathological parameters (Wilcoxon rank sum test and Chi-square test for two independent groupings and Jonckheere\'s test for ordered medians (JTOM)). As there was a maximum of four scores for TF expression available for each patient, the mean scores were taken for statistical analysis. The scores for intensity (*I*) and percentage (*P*) were substituted in a formula to obtain a scale. The formula was decided to be 100\**I*~s~+*P*~s~, which produced a scale ranging from 0--500 for TF expression in terms of strongest intensity (*I*~s~). A score of \>310 was used as a cut-off for positivity. The cut-off was chosen in order to mimic the criteria for positivity used by [@bib26]. Scores based on the intensity (*I*~m~) of the majority of cancer cells stained were also recorded and the formula *I*~m~\**P*~m~ was used to obtain a scale of 0--400 for tissue expression. This scale was compared against clinicopathological parameters to observe for trend differences in comparison with the ones when strongest intensity (100\**I*~s~+*P*~s~) was emphasised in scoring the specimens. The Kaplan--Meier method was used to compare the survival data of 160 patients to TF expression. Survival time was measured as the time from the date of surgery until death or last follow-up appointment. The significance of the difference between the variables was calculated by a Log-rank test on these data.

Results
=======

Immunohistochemical staining of TF in gastric cancer
----------------------------------------------------

In normal mucosa, moderate to strong staining (scores 2 and 3) was seen in the parietal and chief cells at the basal pits. There was an associated mixed chronic inflammatory cell infiltrate (lymphocytes/mast cells) in the submucosa that also stained strongly. None of the ductal structures in the normal gastric samples (*n*=13) stained. As only ductal structures were relevant, all normal tissue was considered negative for TF expression. Only 2 out of the 18 intestinal metaplasia samples stained positive for TF (TF\>310) but, when staining was present, it was at a high intensity. The staining intensity of intestinal metaplasia samples ranged from score 1 to 3, with a majority having score 3, but with a small percentage, mean 6% and range 0--15%. Staining was seen in tumour-cell cytoplasm and cell membrane. The staining pattern was heterogeneous in intensity and percentage of stained cells. The staining intensity was relatively concentrated in signet ring cells and carcinoma cells situated near the vessel endothelium. In all, 43 out of 160 (27%) tumours were classified positive for TF. The other 117 cases (73%) demonstrated a staining intensity that was weaker than that found in the majority of intestinal metaplasia samples, but with a much higher percentage of cells being stained and these were classified as TF negative ([Figure 1A--F](#fig1){ref-type="fig"}). All negative controls showed no immunoreactivity. There was a trend for increased TF positivity along the adenoma--carcinoma sequence. ([Table 2](#tbl2){ref-type="table"}; [Figure 2](#fig2){ref-type="fig"}). The increasing trend for TF expression against overall stage 0--4 gastric adenocarcinoma was more significant for the alternative scoring method (*P*=0.01; ([Figure 2A](#fig2){ref-type="fig"}) when compared with the *I*~m~ scale (*P*=0.025; [Figure 2B](#fig2){ref-type="fig"}) by JTOM. Moreover, by taking into account the normal and intestinal metaplasia tissue to examine TF expression along the gastric MACS, the increasing trend was shown to be highly significant in both approaches; *P*\<0.0001 by JTOM for both *I*~s~ and *I*~m~ scales ([Figure 2](#fig2){ref-type="fig"}). *P*-value was more significant in the approach where *I*~m~ and *P*~m~ of stained cells were recorded. However, trends of increase in TF expression were not found to be significant by JTOM with other clinicopathological features (tumour differentiation, residual resection margins, T staging, N staging and M staging) in both approaches. The was no statistically significant difference in MVD of gastric adenocarcinoma with positive (*n*=25) *vs* negative (*n*=25) TF expression.

Clinicopathological features and TF expression
----------------------------------------------

### The association between TF expression and clinicopathological parameters is presented in 100\**I*~s~+*P*~s~

The above formulae and a cut-off of 310 was chosen to produce results that could be compared with the findings in [@bib26], where gastric cancer cells were scored as TF positive when \>10% of cells stained intensely.

No significant differences were detected between positive TF expression and most of the clinicopathological features (gender, location, histological appearance, T staging, N staging and M staging), with the exception of overall TNM staging. The difference, tested by Chi-square test was significant when the overall TNM staging was grouped as 0--2 *vs* 3--4, *P*=0.04. This supports the finding of an ordered increase in TF expression from stage 0 to stage 4, *P*=0.01. The differences in N staging had borderline significance, *P*=0.054, with 31% of patients having positive lymph-node status compared with 19% patients with negative lymph-node status expressing TF\>310. Similar trends for TF expression against clinicopathological parameters were seen when using the *I*~m~ (*I*~m~\**P*~m~) method.

In Lauren subtypes, no significant relationship was found between positive TF expression (TF\>310) and clinicopathological parameters. However, a borderline significant trend was seen for a relationship between TF expression and T (*P*=0.07) and N stage (*P*=0.06) for diffuse-type gastric adenocarcinoma. The was no relationship between TF expression and prognosis ([Figure 3A--D](#fig3){ref-type="fig"}).

Discussion
==========

TF expression and its relationship with treatment outcome in gastric adenocarcinoma has been reported previously in Japan ([@bib26]). Our report is the first study to look at TF expression along the MACS of gastric adenocarcinoma and to investigate the relationship with prognosis in a European population. In this study, immunohistochemistry involved recording both the strongest intensity of staining (*I*~s~) and the intensity for the majority of cells stained (*I*~m~) and their respective percentages to study the influence of different scoring methods on the relationship between TF expression and outcomes. With the 100\**I*~s~+*P*~s~ scale ([Figure 2A](#fig2){ref-type="fig"}), the intestinal metaplasia gastric cells exhibit a higher peak in positive TF expression (TF\>310) than those in stage 0 cancer. In the *I*~m~\**P*~m~ scale, TF expression of intestinal metaplasia cells would still record a lower value than stage 0 cancer, giving a smooth increasing trend for TF expression. Although found in many studies ([@bib11]; [@bib12]), we were unable to confirm the high MVD in high TF-expressing tumours. This may be due to the intrinsic biological difference or different staging systems between European and East Asian gastric cancers. There are main differences in distribution of gastric cancers in these two hemispheres, which include tumour location, with more distal or middle thirds involvement in Japanese patients, and Lauren subtypes, predominantly the intestinal type in Japan. Our study has shown that TF expression was present in intestinal metaplasia gastric cells, with stronger TF staining intensities but lower percentages compared with lower stage cancers.

There are very similar trends in TF expression with clinicopathological parameters in both our and the previously reported approaches. With the scale that placed emphasis on intensity of staining (100\**I*~s~+*P*~s~), a more significant result was found, *P*=0.01, for the increasing trend of TF expression in stages 0--4 gastric adenocarcinoma. Looking at the adenoma--carcinoma sequence on the whole, the increasing trend was very significant, *P*\<0.0001, for the TF expression from normal tissue, intestinal metaplasia and throughout all stages of gastric adenocarcinoma. A similar outcome was found in the *I*~m~\**P*~m~ approach. The increasing trend in the *I*~m~\**P*~m~ scale indicates that both intensity and percentage of TF expression increase with stages of gastric cancer. When the results were narrowed down to cut-off values and into subdivided groupings of clinicopathological parameters, there are different outcomes for two scales in the aspect of overall TNM staging. A slight significant difference, *P*=0.04 was found with the 100\**I*~s~+*P*~s~ scale rather than with the *I*~m~\**P*~m~ scale, *P*=0.24. Difference in outcome might reflect the impact of intensity of TF staining being stronger compared with percentage staining in determining the relationship with overall TNM staging. It also reflects that the different approach in scoring can influence outcome.

This study has not been able to confirm a higher TF expression in intestinal-type cancers, found in [@bib26] (28% intestinal-type and 33% diffuse-type cancers). Diffuse-type cancers are known to be more invasive and have a poorer prognosis compared with intestinal types. TF has been related to cancer metastasis in many studies; its relationship with invasiveness could be highlighted in this study with the slightly higher proportion of diffuse-type cancers being TF positive. There was no significant difference found between M staging and positive TF expression in our gastric cancer series. We were unable to confirm the significant relationship between TF expression and survival specifically in intestinal-type gastric cancer, as demonstrated in the Japanese group. Although a significant increase in TF expression was found with advancing stage, which is a good predictor of survival outcome, no relationship was seen. The huge variation in TF expression across all the stages of gastric cancer suggests that factors other than TF are influencing survival. As with the different outcomes with the roles of TF and FVIIa in signal transduction in different cell types, there may be a genetic variation in the propensity for TF expression in gastric cancer cells of different individuals of the same population. This is supported by various studies concluding in the nature of FVIIa:TF-induced signalling as being variable and cell-type-dependent ([@bib5]; [@bib3]; [@bib25]; [@bib23]). As TF could act as a receptor for FVIIa in activating many cellular pathways, further work could be done to research the role of FVIIa and their relationship with VEGF and MVD. This would help us determine whether TF or FVIIa could cause angiogenic switch early on before the gastric cancer stages.

In conclusion, this study found no TF expression in normal gastric mucosal cells. A strong intensity staining was found in intestinal metaplasia cells but in a small percentage of samples. We confirmed that TF expression increases with advancing stage of gastric cancer. In contrast to previous Japanese study, findings in this Western population support a slightly higher proportion of positive TF expression in diffuse subtypes, correlating with their more invasive behaviour. Different approaches to scoring could potentially affect outcomes in studies that involve immunohistochemical staining. An approach that utilises the strongest intensity score observed in specimens and its percentage seems to give a significant result for positive expression (TF\>310) in influencing overall TNM staging. TF expression also displays a huge variation across all gastric cancer stages in different individuals of the same population and is not significantly associated with survival outcome.
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![(**A**) Normal gastric tissue with negative TF staining. (**B**) Intestinal metaplasia with strong TF staining at edges of ductal structures. (**C**) Weak staining (score 1 (*I*); 100% (*P*)) of gastric cancer cells. (**D**) Moderate staining (score 2 (*I*); 100% (*P*)) in gastric cancer cells. (**E**) Strong staining (score 3 (*I*); 80% (*P*)) in gastric cancer cells. (**F**) Very strong staining (score 4 (*I*); 100% (*P*)) in gastric cancer cells.](bjc2012363f1){#fig1}

![(**A**) Increasing TF expression with (100\* *I*~s~+*P*~s~) scale across the gastric adenoma--carcinomic sequence with JTOM; *P*\<0.0001. (**B**) Increasing TF expression with (*I*~m~\**P*~m~) scale across the gastric adenoma--carcinomic sequence with Jockheere\'s test for ordered medians; *P*\<0.0001.](bjc2012363f2){#fig2}

![(**A**) Survival outcome in TF positive (TF\>310) cancers. (**B**) Survival outcome in diffuse-type TF-positive cancers. (**C**) Survival outcome in intestinal-type TF-positive cancers. (**D**) Survival outcome in patients with Stage 0--4 gastric adenocarinoma.](bjc2012363f3){#fig3}

###### Patient demographics of samples examined for TF expression

  **Sample**              ***n***   **Male:female**   **Mean age**
  ----------------------- --------- ----------------- -------------------
  Normal                  13        7 : 6             61
  Intestinal Metaplasia   18        5 : 13            67.7
  Adenocarcinoma          160       122 : 58          67 (range 30--85)

###### Increasing TF expression along the gastric adenoma--carcinoma sequence

  **Tissue type**           **Patients**   **TF positive**[a](#t2-fn2){ref-type="fn"}
  ------------------------- -------------- --------------------------------------------
  Normal mucosa             0/13           0%
                                            
  *Intestinal metaplasia*   2/18           11%
   Stage 0                  0/2            0%
   Stage 1                  5/27           19%
   Stage 2                  11/52          21%
   Stage 3                  21/68          31%
   Stage 4                  6/11           55%

Increasing expression with gastric cancer progression was significant with Jonckheere\'s test for ordered medians; *P*=0.0005.

Positive expression=100\**I*~s~+*P*~s~ \>310
